InvestoGain

Investogain Pty Limited
AFS Licence No. 334036

All correspondence to:
admin@delisted.com.au
or by mail to:
PO Box 400
Crows Nest NSW 1585

26 April 2025

Name:	G MEDICAL INNOVATIONS HOLDINGS LIMITED (GMV)
ISIN:	KYG394621091
Date of Listing:	10 May 2017
Date of Delisting:	23 October 2020

Stock Exchange Status: (updated daily)

This entity was delisted from the Australian Securities Exchange on 23 October 2020.

Legal Status: (updated monthly)

ACN: 617 204 743
Registration Date: 24 February 2017

To our knowledge this is a current registered entity, not in any form of external administration. If you have questions about your shareholding they may be taken up with us here: https://www.delisted.com.au/TraceLostSharesLostMoney/index/.

Capital Gains Tax (CGT) Status: (updated at least quarterly)

The securities in this entity, in our opinion, are of little or no value. We have made that assessment by reference to the circumstances leading to a suspension and/or delisting, the length of a suspension, share trading history and last on-market share price, most recent financial and cash flow statements, prospects (including likelihood of re-financing), and other factors including in particular whether the entity is in external administration. If you are seeking to crystallise a capital loss on your securities, that process can be easily and quickly initiated at our online Worthless Shares facility here: https://www.delisted.com.au/sell-worthless-and-other-securities/.

Updates, corrections, disagreements please email to admin@delisted.com.au

Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.

Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.

Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.

G MEDICAL INNOVATIONS HOLDINGS LIMITED(GMV)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

Shareholder links

Our website ranking of GMV:

(5 out of 5)

COMPANY WEBSITE:

GMV website

GMV email

GMV investorRelations

GMV announcements

GMV annualreports

REGISTRY:

Level 5, 191 ST GEORGES TERRACE PERTH WA 6000

Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
Fax :
RegistryWebsite RegistryEmail

Company details

ISIN: KYG394621091

Address: c/o G Medical Diagnostic Services, Inc. 1500 Lakeside Dr. Ste 115 Bannockburn, IL 60015 USA
Tel: +1 345 749 2000 Fax:

Date first listed: 10/05/2017
Company Secretary:
Sector: Health Care Equipment & Services Industry Group:
Activities: mHealth and e-health solutions The Company specialises in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories

News & Events

Expand this box to read and print

Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.	10/07/2024
delisted from the close of trading on Friday, 23 October 2020, pursuant to Listing rule 17.11.	23/10/2020
we understand the company proposes to list on NASDAQ, seeks to raise funds by way of a public offering in the US and believes it is not economical to maintain its ASX listing	23/10/2020
The company has publicly filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a potential public offering of ordinary shares on the Nasdaq Global Market.	02/10/2020
The company releases an Appendix 2A.	30/09/2020
An Extraordinary General Meeting of the Company will be held at G Medical Innovations Holdings Ltd's Tel Aviv Office, 3rd Floor, 5 Oppenheimer Street, Rehovot, Israel 7670105 held on 29 October 2020 commencing at 9am (Tel Aviv).	29/09/2020
The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, following approval by GMV shareholders for removal of GMV from the Official List of ASX.	21/09/2020
The securities of G Medical Innovations Holdings Ltd will be reinstated to Official Quotation as from the commencement of trading on Wednesday, 8 April 2020 following lodgement of its Annual Report for the year(s) ended 31 December 2019.	07/04/2020
The company releases a notice of Proposed issue of Securities - GMV.	07/04/2020
The company has entered into a deed of variation to extend the repayment date of the settlement sum owing to MEF I,L.P. under the deed of termination, settlement and release to 30 April 2020. The company has also agreed to issue to Magna on or before 30 April 2020 such number of fully paid ordinary shares in the company equivalent to US$260,000. The settlement sum owing and payable to Magna will be reduced by US$130,000 and, as at the date of this announcement, the company will repay to Magna an amount of US$3,260,665 by 30 April 2020 in full and final settlement of the company's outstanding debt to Magna.	07/04/2020
The company releases an Appendix 4G.	07/04/2020
The company lodges its Annual Report.	07/04/2020
Prizma now licensed for use in Taiwan by Taiwan Food and Drug Administration. Prizma device can detect and monitor symptoms associated with infection and acute and chronic illness. Significant achievement allows GMV to progress Taiwan market entry. Commercial negotiations are ongoing G Medical's existing in country partners.	06/04/2020
Prizma now registered on Italian Health Ministry Database of medical products. Prizma device can detect and monitor symptoms associated with infection and acute and chronic illness "“ device has the potential to alleviate pressure on hospitals and clinics. First Prizma units ordered and purchased by Meditel in expedited market initiative. GMV and Meditel confident of significant uptake as demand for telehealth and e-health technologies and services increases.	06/04/2020
G Medical is currently experiencing business disruptions due to the national emergency in Israel, as well as broader shutdowns in the United States, China and Australia as a result of the COVID-19 pandemic. These interruptions have left G Medical unable to compile and finalise the relevant documentation required for its 2019 annual report. G Medical is working with internal parties and BDO to finalise its financial report and lodge them as soon as possible.	31/03/2020
The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, pending the release of an announcement regarding an update on the registration status of GMV's products and the lodgement of its audited annual report for the year ended 31 December 2019.	31/03/2020
The suspension of trading in the securities of G Medical Innovations Holdings Limited will be lifted immediately, following the release by GMV of an announcement regarding a funding facility.	04/12/2019
A$30m funding facility secured to significantly fast track US and global sales growth of its market leading Prizma and VSMS patch. GMV to capitalise on immediate growth opportunities and expand US sales force 4-fold. Funding secured from top tier financial institution GEM Global and can be drawn at GMV's discretion. Product suite gaining significant traction with multiple opportunities developing in USA and other markets. Considerable near-term value drivers expected from end of H1 2020 and going forward. GEM's decision to fund GMV is a vote of confidence to the future growth of the company.	04/12/2019
The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, pending the release of an announcement regarding a funding facility.	29/11/2019
The suspension of trading in the securities of G Medical Innovations Holdings Limited will be lifted from the commencement of trading on Tuesday, 22 October 2019, following the receipt of a response to an ASX Query.	22/10/2019
The company issues a response to ASX Query.	22/10/2019
The company issues a response to ASX Query.	09/10/2019
The company is in the process of preparing a response to an ASX query and will provide further updates at the appropriate time.	02/10/2019
ASX has suspended the securities of G Medical Innovations Holdings Limited from official quotation pursuant to Listing Rule 17.3, for failure to respond to an ASX query. The suspension will continue until the Company provides a satisfactory response to ASX's query.	17/09/2019
The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, pending the response to an ASX query letter.	10/09/2019
The securities of G Medical Innovations Holdings Limited will be reinstated to Official Quotation as from the commencement of trading on Tuesday, 5 March 2019 following lodgement of its Appendix 4E Preliminary Final Report for the year(s) ended 31 December 2018.	04/03/2019
The company releases an Appendix 4G.	04/03/2019
The company lodges its Appendix 4E and Annual Financial Statements.	04/03/2019
The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, pending the release of the Company's preliminary final report.	28/02/2019
The suspension of trading in the securities of G Medical Innovations Holdings Limited will be lifted immediately following receipt of an announcement.	10/11/2017
The company has executed a binding memorandum of understanding between its subsidiary, G Medical Innovations Asia Limited and First Channel for the distribution of G Medical's products and services in India and Taiwan.	10/11/2017
The securities of G Medical Innovations Holdings Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement.	08/11/2017
listed entity carried for record purposes only	10/05/2017

Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.	10/07/2024
delisted from the close of trading on Friday, 23 October 2020, pursuant to Listing rule 17.11.	23/10/2020
we understand the company proposes to list on NASDAQ, seeks to raise funds by way of a public offering in the US and believes it is not economical to maintain its ASX listing	23/10/2020
The company has publicly filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a potential public offering of ordinary shares on the Nasdaq Global Market.	02/10/2020
The company releases an Appendix 2A.	30/09/2020
An Extraordinary General Meeting of the Company will be held at G Medical Innovations Holdings Ltd's Tel Aviv Office, 3rd Floor, 5 Oppenheimer Street, Rehovot, Israel 7670105 held on 29 October 2020 commencing at 9am (Tel Aviv).	29/09/2020
The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, following approval by GMV shareholders for removal of GMV from the Official List of ASX.	21/09/2020
The securities of G Medical Innovations Holdings Ltd will be reinstated to Official Quotation as from the commencement of trading on Wednesday, 8 April 2020 following lodgement of its Annual Report for the year(s) ended 31 December 2019.	07/04/2020
The company releases a notice of Proposed issue of Securities - GMV.	07/04/2020
The company has entered into a deed of variation to extend the repayment date of the settlement sum owing to MEF I,L.P. under the deed of termination, settlement and release to 30 April 2020. The company has also agreed to issue to Magna on or before 30 April 2020 such number of fully paid ordinary shares in the company equivalent to US$260,000. The settlement sum owing and payable to Magna will be reduced by US$130,000 and, as at the date of this announcement, the company will repay to Magna an amount of US$3,260,665 by 30 April 2020 in full and final settlement of the company's outstanding debt to Magna.	07/04/2020
The company releases an Appendix 4G.	07/04/2020
The company lodges its Annual Report.	07/04/2020
Prizma now licensed for use in Taiwan by Taiwan Food and Drug Administration. Prizma device can detect and monitor symptoms associated with infection and acute and chronic illness. Significant achievement allows GMV to progress Taiwan market entry. Commercial negotiations are ongoing G Medical's existing in country partners.	06/04/2020
Prizma now registered on Italian Health Ministry Database of medical products. Prizma device can detect and monitor symptoms associated with infection and acute and chronic illness "“ device has the potential to alleviate pressure on hospitals and clinics. First Prizma units ordered and purchased by Meditel in expedited market initiative. GMV and Meditel confident of significant uptake as demand for telehealth and e-health technologies and services increases.	06/04/2020
G Medical is currently experiencing business disruptions due to the national emergency in Israel, as well as broader shutdowns in the United States, China and Australia as a result of the COVID-19 pandemic. These interruptions have left G Medical unable to compile and finalise the relevant documentation required for its 2019 annual report. G Medical is working with internal parties and BDO to finalise its financial report and lodge them as soon as possible.	31/03/2020
The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, pending the release of an announcement regarding an update on the registration status of GMV's products and the lodgement of its audited annual report for the year ended 31 December 2019.	31/03/2020
The suspension of trading in the securities of G Medical Innovations Holdings Limited will be lifted immediately, following the release by GMV of an announcement regarding a funding facility.	04/12/2019
A$30m funding facility secured to significantly fast track US and global sales growth of its market leading Prizma and VSMS patch. GMV to capitalise on immediate growth opportunities and expand US sales force 4-fold. Funding secured from top tier financial institution GEM Global and can be drawn at GMV's discretion. Product suite gaining significant traction with multiple opportunities developing in USA and other markets. Considerable near-term value drivers expected from end of H1 2020 and going forward. GEM's decision to fund GMV is a vote of confidence to the future growth of the company.	04/12/2019
The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, pending the release of an announcement regarding a funding facility.	29/11/2019
The suspension of trading in the securities of G Medical Innovations Holdings Limited will be lifted from the commencement of trading on Tuesday, 22 October 2019, following the receipt of a response to an ASX Query.	22/10/2019
The company issues a response to ASX Query.	22/10/2019
The company issues a response to ASX Query.	09/10/2019
The company is in the process of preparing a response to an ASX query and will provide further updates at the appropriate time.	02/10/2019
ASX has suspended the securities of G Medical Innovations Holdings Limited from official quotation pursuant to Listing Rule 17.3, for failure to respond to an ASX query. The suspension will continue until the Company provides a satisfactory response to ASX's query.	17/09/2019
The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, pending the response to an ASX query letter.	10/09/2019
The securities of G Medical Innovations Holdings Limited will be reinstated to Official Quotation as from the commencement of trading on Tuesday, 5 March 2019 following lodgement of its Appendix 4E Preliminary Final Report for the year(s) ended 31 December 2018.	04/03/2019
The company releases an Appendix 4G.	04/03/2019
The company lodges its Appendix 4E and Annual Financial Statements.	04/03/2019
The securities of G Medical Innovations Holdings Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of GMV, pending the release of the Company's preliminary final report.	28/02/2019
The suspension of trading in the securities of G Medical Innovations Holdings Limited will be lifted immediately following receipt of an announcement.	10/11/2017
The company has executed a binding memorandum of understanding between its subsidiary, G Medical Innovations Asia Limited and First Channel for the distribution of G Medical's products and services in India and Taiwan.	10/11/2017
The securities of G Medical Innovations Holdings Limited will be suspended from official quotation immediately at the request of the Company, pending the release of an announcement.	08/11/2017
listed entity carried for record purposes only	10/05/2017

Your browser may reflect a date of printing in American format.

ASX Announcements (courtesy of ASX)

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

Company Updates

Post your comments here

Please read our Terms before posting comments.

Click here for free access to this company's:
ASX, Legal & CGT Status

Directors' on-market share transactions (last 5)

Purchases Sales

DATE	DIRECTOR	NUMBER	PRICE	AMOUNT
22/05/2020	Yacov Geva	-47,125,000	$0.075	$3,534,375.00
03/06/2019	Yacov Geva	742,168	$0.246	$182,566.00
03/04/2018	Yacov Geva	1,036,000	$0.274	$283,876.00
13/02/2018	Ashley Krongold	250,000	$0.302	$75,468.00
07/02/2018	Yacov Geva	1,470,000	$0.299	$438,772.00

Click here for the last 20 transactions all companies

Directors & Executives (current)

NAME	TITLE	DATE OF APPT
Kenneth Melani	Chairman	10/05/2017
Yacov Geva	Managing Director, CEO	10/05/2017
Zeev Rotstein	Non Exec Director	05/03/2019
Urs Wettstein	Director	10/05/2017
Shuki Gleitman	Director	10/05/2017
Brendan de Kauwe	Director	10/05/2017
Brett Tucker	Company Secretary

Date of first appointment, title may have changed.

Directors & Executives (former)

NAME	TITLE	DATE OF APPOINTMENT	DATE OF RESIGNATION

Date of first appointment, title may have changed.